Parkinson's Disease

Circadian homeostasis and neurodegeneration 3:04
Circadian homeostasis and neurodegeneration
Aleksandar Videnovic • 24 Mar 2022
Brain perfusion patterns may predict conversion subtype in iRBD 6:58
Brain perfusion patterns may predict conversion subtype in iRBD
Shady Rahayel • 7 Mar 2022
Brain atrophy in RBD is shaped by gene expression and structural connectivity 6:42
Brain atrophy in RBD is shaped by gene expression and structural connectivity
Shady Rahayel • 7 Mar 2022
The role of TCS in the evaluation of Parkinson’s disease 2:08
The role of TCS in the evaluation of Parkinson’s disease
Claudia Trenkwalder • 11 Mar 2022
Issues in fetal tissue transplantation for Parkinson’s disease 2:31
Issues in fetal tissue transplantation for Parkinson’s disease
Clive Svendsen • 15 Mar 2022
Ex vivo gene therapy for neurodegenerative diseases 2:20
Ex vivo gene therapy for neurodegenerative diseases
Clive Svendsen • 15 Mar 2022
Key clinical trials of disease modifying therapies in Parkinson’s disease 2:12
Key clinical trials of disease modifying therapies in Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Phase II trial of ambroxol as a disease modifying therapy for Parkinson’s disease dementia 8:59
Phase II trial of ambroxol as a disease modifying therapy for Parkinson’s disease dementia
Stephen Pasternak • 16 Mar 2022
Update on biomarkers in isolated RBD and future directions 4:28
Update on biomarkers in isolated RBD and future directions
Mitchell Miglis • 3 Mar 2022
The current state of knowledge in brain changes in patients with iRBD 1:19
The current state of knowledge in brain changes in patients with iRBD
Shady Rahayel • 7 Mar 2022
Alpha-synuclein as a therapeutic target for Parkinson’s disease 2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Searching for therapeutic targets for Parkinson’s disease 1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease 1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Future prospects in Parkinson’s disease 1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Questioning the Braak hypothesis in Parkinson’s disease 3:42
Questioning the Braak hypothesis in Parkinson’s disease
Alberto Espay • 9 Sep 2021
Is clearing α-synuclein enough to treat Parkinson’s disease? 2:49
Is clearing α-synuclein enough to treat Parkinson’s disease?
Alberto Espay • 9 Sep 2021
The content of VJNeurology is intended for healthcare professionals